Home     About Us     Team     Products     News     Contact     FAQ     Account

Multikinase Inhibitors

Kisqali Femara Co-Pack (letrozole/ribociclib)

KISQALI® (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.



Manufacturer's Website: Kisqali                                                                                                                                           Average retail cost: $2,800/month

Iclusig (ponatinib)

Ponatinib (trade name Iclusig) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)... Wikipedia



Manufacturer's Website: Iclusig                                                                                                                                           Average retail cost: $5,400/month

Zelboraf (vemurafenib)

Vemurafenib (INN, marketed as Zelboraf) is a B-Raf enzyme inhibitor developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma... Wikipedia



Manufacturer's Website: Zelboraf                                                                                                                                           Average retail cost: $5,500/month

Jakafi (ruxolitinib)

Ruxolitinib (trade name Jakafi) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea... Wikipedia



Manufacturer's Website: Jakafi                                                                                                                                           Average retail cost: $5,900/month

Caprelsa (vandetanib)

Vandetanib (INN, trade name Caprelsa) is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase... Wikipedia



Manufacturer's Website: Caprelsa                                                                                                                                          Average retail cost: $6,600/month

Cotellic (cobimetinib)

Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech (Roche). It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma... Wikipedia



Manufacturer's Website: Cotellic                                                                                                                                          Average retail cost: $6,900/month

Zykadia (ceritinib)

Ceritinib (INN, trade name Zykadia /zaɪˈkeɪdiːə/ zy-KAY-dee-ə) is a prescription-only drug used for the treatment non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014... Wikipedia



Manufacturer's Website: Zykadia                                                                                                                                          Average retail cost: $6,900/month

Rydapt (midostaurin)

Midostaurin (sold under the name Rydapt) is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis... Wikipedia



Manufacturer's Website: Rydapt                                                                                                                                          Average retail cost: $7,700/month

Ofev (nintedanib)

Nintedanib, marketed under the brand names Ofev and Vargatef, is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer... Wikipedia



Manufacturer's Website: Ofev                                                                                                                                          Average retail cost: $8,000/month

Gilotrif (afatinib)

Afatinib (INN; trade name Gilotrif in the US) is a drug approved in United States, Europe, Taiwan, Mexico, Chile and Japan as well as other countries for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim... Wikipedia



Manufacturer's Website: Gilotrif                                                                                                                                         Average retail cost: $8,200/month

Tafinlar (dabrafenib)

Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma... Wikipedia



Manufacturer's Website: Tafinlar                                                                                                                                         Average retail cost: $9,800/month

Zydelig (idelalisib)

Idelalisib (trade name Zydelig codenamed GS-1101 or CAL-101) is a drug used for the treatment of certain hematological malignancies. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase... Wikipedia



Manufacturer's Website: Zydelig                                                                                                                                        Average retail cost: $9,700/month

Mekinist (trametinib)

Trametinib (trade name Mekinist) is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial... Wikipedia



Manufacturer's Website: Mekinist                                                                                                                                        Average retail cost: $10,600/month

Ibrance (palbociclib)

The drug was reviewed and approved under the Food and Drug Administration’s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer... Wikipedia



Manufacturer's Website: Ibrance                                                                                                                                        Average retail cost: $11,200/month

Imbruvica (ibrutinib)

Ibrutinib (Imbruvica) is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma... Wikipedia



Manufacturer's Website: Imbruvica                                                                                                                                       Average retail cost: $11,300/month

Alecensa (alectinib)

Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC)... Wikipedia



Manufacturer's Website: Alecensa                                                                                                                                       Average retail cost: $13,600/month

Xalkori (crizotinib)

Crizotinib (trade name Xalkori, Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children... Wikipedia



Manufacturer's Website: Alecensa                                                                                                                                       Average retail cost: $13,600/month

Cometriq (cabozantinib)

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others... Wikipedia



Manufacturer's Website: Cometriq                                                                                                                                       Average retail cost: $15,100/month

Stivarga (regorafenib)

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types... Wikipedia



Manufacturer's Website: Stivarga                                                                                                                                       Average retail cost: $15,200/month

Cabometyx (cabozantinib)

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others... Wikipedia



Manufacturer's Website: Cabometyx                                                                                                                                       Average retail cost: $16,300/month

Sutent (sunitinib)

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006... Wikipedia



Manufacturer's Website: Sutent                                                                                                                                       Average retail cost: $16,600/month

Nexavar (sorafenib)

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma... Wikipedia



Manufacturer's Website: Nexavar                                                                                                                                       Average retail cost: $16,800/month

Rozlytrek (entrectinib)

Entrectinib, trade name Rozlytrek previously known as RXDX-101 and NMS-E628) is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019... Wikipedia



Manufacturer's Website: Rozlytrek                                                                                                                                      Average retail cost: $17,100/month

Vitrakvi (larotrectinib)

Larotrectinib (tradename Vitrakvi) is a drug for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Larotrectinib was initially awarded orphan drug status in 2015 for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA. Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is "tissue agnostic")... Wikipedia



Manufacturer's Website: Vitrakvi                                                                                                                                    Average retail cost: $33,800/month

Copyright 2006-2020 Automated Clinical Guidelines, LLC. All rights reserved.